Addex Therapeutics Ltd

Addex Therapeutics Ltd에 대해 보유한 최신 분기

2025년 6월 30일에 끝난 분기를 1년 전 같은 분기와 비교합니다.

이것은 단일 분기 수치이며 최근 1년치가 아닙니다. 이 사이트의 다른 수치는 12개월을 다루므로 훨씬 큽니다. 계절성이 있는 사업은 둘 사이의 차이가 큽니다. 서비스나우는 12월 분기에 20억 달러의 잉여현금흐름을 벌지만 6월 분기에는 5억 달러입니다.

애널리스트 전망이 아니라 1년 전 같은 분기와 비교했습니다. “서프라이즈”나 “쇼크”를 말하려면 컨센서스 추정치가 필요한데, 이는 우리가 보유하지 않은 라이선스 데이터입니다. 잘못 말하는 것이 아예 말하지 않는 것보다 나쁩니다.

실적 발표 컨퍼런스 콜

Addex Therapeutics Ltd의 실적 발표 콜 녹취록이 없습니다.

경영진의 발언

“The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABAB cough program towards clinical development. Coupled with recent regaining of all rights to the GABAB PAM program for substance use disorders from Indivior, due to R&D rationalization following its merger with Supernus Pharmaceuticals, providing a valuable asset for Addex and solidifying our leading portfolio of drug candidates targeting GABAB receptor biology . Our spin-out company, Neurosterix made as well great progress and is on track to complete its Phase 1 clinical study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, during the fourth quarter of 2026,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

Addex Therapeutics Ltd은(는) 무엇을 하는 기업인가

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, ​ psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ ADXN ” on each exchange.

발표 자료 말미에 실린 기업 자신의 소개글입니다.